Patent ID: 7771722

Claim:
A method to diagnose clinical Alzheimer's disease in a subject comprising: (a) administering to said subject an amount of an antibody which specifically binds an epitope contained within positions 13-28 of Aβ and increases clearance of soluble and bound forms of Aβ from the central nervous system, wherein said amount is effective to increase the levels of circulating Aβ peptides in the blood of said subject when said subject is in a clinical stage of Alzheimer's disease; (b) measuring the level of at least one of Aβ 40 or Aβ 42 , or the ratio of Aβ 40 /Aβ 42 in the blood of said subject at a time interval after said administering; and (c) comparing the measured level of Aβ 40 or Aβ 42 , or the measured ratio of Aβ 40 /Aβ 42 in said subject with a control value of said level or of said ratio, wherein an elevated measured level of Aβ 40 or Aβ 42 or of the ratio of Aβ 40 /Aβ 42 in said subject as compared to said control value identifies said subject as in a clinical stage of Alzheimer's disease.